Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Value of baseline platelet count for prediction of complications in primary biliary cirrhosis patients treated with ursodeoxycholic acid.

Huang YL, Yao DK, Hu ZD, Sun Y, Chen SX, Zhong RQ, Deng AM.

Scand J Clin Lab Invest. 2013 Feb;73(1):17-23. doi: 10.3109/00365513.2012.731709. Epub 2013 Jan 7.

PMID:
23294193
2.

Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response.

Trivedi PJ, Bruns T, Cheung A, Li KK, Kittler C, Kumagi T, Shah H, Corbett C, Al-Harthy N, Acarsu U, Coltescu C, Tripathi D, Stallmach A, Neuberger J, Janssen HL, Hirschfield GM.

J Hepatol. 2014 Jun;60(6):1249-58. doi: 10.1016/j.jhep.2014.01.029. Epub 2014 Feb 15.

PMID:
24548531
3.

Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.

Lammers WJ, Hirschfield GM, Corpechot C, Nevens F, Lindor KD, Janssen HL, Floreani A, Ponsioen CY, Mayo MJ, Invernizzi P, Battezzati PM, Parés A, Burroughs AK, Mason AL, Kowdley KV, Kumagi T, Harms MH, Trivedi PJ, Poupon R, Cheung A, Lleo A, Caballeria L, Hansen BE, van Buuren HR; Global PBC Study Group.

Gastroenterology. 2015 Dec;149(7):1804-1812.e4. doi: 10.1053/j.gastro.2015.07.061. Epub 2015 Aug 7.

PMID:
26261009
4.

Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis?

Kilmurry MR, Heathcote EJ, Cauch-Dudek K, O'Rourke K, Bailey RJ, Blendis LM, Ghent CN, Minuk GY, Pappas SC, Scully LJ, Steinbrecher UP, Sutherland LR, Williams CN, Worobetz LJ.

Hepatology. 1996 May;23(5):1148-53.

PMID:
8621147
5.

Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis.

Bonnand AM, Heathcote EJ, Lindor KD, Poupon RE.

Hepatology. 1999 Jan;29(1):39-43.

PMID:
9862847
6.

Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid.

Angulo P, Lindor KD, Therneau TM, Jorgensen RA, Malinchoc M, Kamath PS, Dickson ER.

Liver. 1999 Apr;19(2):115-21.

PMID:
10220741
7.

Predictive scores in primary biliary cirrhosis: a retrospective single center analysis of 204 patients.

Weinmann A, Sattler T, Unold HP, Grambihler A, Teufel A, Koch S, Schuchmann M, Biesterfeld S, Wörns MA, Galle PR, Schulze-Bergkamen H.

J Clin Gastroenterol. 2015 May-Jun;49(5):438-47. doi: 10.1097/MCG.0000000000000176.

PMID:
25014239
8.

Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.

Kuiper EM, Hansen BE, de Vries RA, den Ouden-Muller JW, van Ditzhuijsen TJ, Haagsma EB, Houben MH, Witteman BJ, van Erpecum KJ, van Buuren HR; Dutch PBC Study Group.

Gastroenterology. 2009 Apr;136(4):1281-7. doi: 10.1053/j.gastro.2009.01.003. Epub 2009 Jan 14.

PMID:
19208346
9.

Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. Dutch Multi-Centre PBC Study Group.

van Hoogstraten HJ, Hansen BE, van Buuren HR, ten Kate FJ, van Berge-Henegouwen GP, Schalm SW.

J Hepatol. 1999 Aug;31(2):256-62.

PMID:
10453938
10.

Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis.

Corpechot C, Poujol-Robert A, Wendum D, Galotte M, Chrétien Y, Poupon RE, Poupon R.

Liver Int. 2004 Jun;24(3):187-93.

PMID:
15189267
11.

Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.

Färkkilä M, Rautiainen H, Kärkkäinen P, Karvonen AL, Nurmi H, Niemelä O.

Liver Int. 2008 Jul;28(6):787-97. doi: 10.1111/j.1478-3231.2008.01722.x.

PMID:
18397236
12.

Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.

Corpechot C, Abenavoli L, Rabahi N, Chrétien Y, Andréani T, Johanet C, Chazouillères O, Poupon R.

Hepatology. 2008 Sep;48(3):871-7. doi: 10.1002/hep.22428.

PMID:
18752324
13.

Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group.

Poupon RE, Bonnand AM, Chrétien Y, Poupon R.

Hepatology. 1999 Jun;29(6):1668-71.

PMID:
10347106
14.

Primary biliary cirrhosis: Dutch application of the Mayo Model before and after orthotopic liver transplantation.

van Dam GM, Verbaan BW, Therneau TM, Dickson ER, Malinchoc M, Murtaugh PA, Huizenga JR, Gips CH.

Hepatogastroenterology. 1997 May-Jun;44(15):732-43.

PMID:
9222682
15.

Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients.

ter Borg PC, Schalm SW, Hansen BE, van Buuren HR; Dutch PBC Study Group.

Am J Gastroenterol. 2006 Sep;101(9):2044-50. Epub 2006 Jul 18.

PMID:
16848809
16.

Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis.

Almasio PL, Floreani A, Chiaramonte M, Provenzano G, Battezzati P, Crosignani A, Podda M, Todros L, Rosina F, Saccoccio G, Manenti F, Ballardini G, Bianchi FP, Scheuer PJ, Davies SE, Craxì A.

Aliment Pharmacol Ther. 2000 Dec;14(12):1645-52.

17.

A validated clinical tool for the prediction of varices in PBC: the Newcastle Varices in PBC Score.

Patanwala I, McMeekin P, Walters R, Mells G, Alexander G, Newton J, Shah H, Coltescu C, Hirschfield GM, Hudson M, Jones D.

J Hepatol. 2013 Aug;59(2):327-35. doi: 10.1016/j.jhep.2013.04.010. Epub 2013 Apr 19.

PMID:
23608623
18.

Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.

Charatcharoenwitthaya P, Pimentel S, Talwalkar JA, Enders FT, Lindor KD, Krom RA, Wiesner RH.

Liver Transpl. 2007 Sep;13(9):1236-45.

19.

Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome.

Corpechot C, Chazouillères O, Poupon R.

J Hepatol. 2011 Dec;55(6):1361-7. doi: 10.1016/j.jhep.2011.02.031. Epub 2011 Apr 13.

PMID:
21703194
20.

Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis.

Yamazaki K, Suzuki K, Nakamura A, Sato S, Lindor KD, Batts KP, Tarara JE, Kephart GM, Kita H, Gleich GJ.

Hepatology. 1999 Jul;30(1):71-8.

PMID:
10385641
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk